Subtype
Tenosynovial Giant Cell Tumor
CI-CAN-00001563TGCTExplore in graph →
Non-malignant9 active trials
- NCIt
- C3402
- DOID
- 314
- MeSH
- D000070779
Loading cancer entity…
Subtype
CI-CAN-00001563TGCTExplore in graph →
Clinical trials
25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT04192344 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 276 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT01804530 |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials
| Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors |
| terminated |
| Phase 1 |
| 59 |
| PlexxikonINDUSTRY |
| 1 |
| Aug 2, 2018 |
| clinicaltrials |
| NCT02673736 | A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor | terminated | Phase 1 | 11 | PlexxikonINDUSTRY | 1 | Aug 2, 2018 | clinicaltrials |